Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma

Table 2

(a) Serum levels of sIL-2R, sB7-H3, and sCTLA-4 in the patients with CCRCC and healthy control groups. (b) Correlation between serum levels of sIL-2R, sB7-H3, and sCTLA-4 and pathological grade in patients with CCRCC. (c) Correlation between serum levels of sIL-2R, sB7-H3, and sCTLA-4 and clinical stage in patients with CCRCC.

(a)

Serum levels	RCC patients	Control groups	𝑃 value
sIL-2R (pg/mL ± SD)	1080.2 ± 1251.3	587.4 ± 210.4	𝑃=0.043
sB7-H3 (ng/mL ± SD)	14.5 ± 10.1	19.3 ± 5.3	𝑃<0.0001
sCTLA-4 (ng/mL ± SD)	2.3 ± 0.7	3.0 ± 1.3	𝑃<0.001

CCRCC: clear cell renal cell carcinoma, sIL-2R: soluble interleukin-2 receptor, sB7-H3: soluble B7-H3, and sCTLA-4: soluble cytotoxic T lymphocyte associated antigen-4.

(b)

	Grade 1	Grade 2	Grade 3	𝑃 value
sIL-2R (pg/mL ± SD)	767.0 ± 547.0	1141.8 ± 1464.4	1287.7 ± 815.3	𝑃=0.178
sB7-H3 (ng/mL ± SD)	13.2 ± 6.0	15.0 ± 11.5	13.9 ± 8.0	𝑃=0.946
sCTLA-4 (ng/mL ± SD)	2.2 ± 0.5	2.4 ± 0.8	2.1 ± 0.6	𝑃=0.533

CCRCC: clear cell renal cell carcinoma, sIL-2R: soluble interleukin-2 receptor, sB7-H3: soluble B7-H3, and sCTLA-4: soluble cytotoxic T lymphocyte associated antigen-4.

(c)

	Stage 1	Stage 2	Stage 3	Stage 4	𝑃-value
sIL-2R (pg/mL ± SD)	687.9 ± 497.4	725.1 ± 740.6	725.3 ± 460.9	2021.9 ± 1922.4	𝑃<0.001
sB7-H3 (ng/mL ± SD)	14.7 ± 12.4	10.2 ± 2.5	12.2 ± 6.9	17.4 ± 9.3	𝑃=0.044
sCTLA-4 (ng/mL ± SD)	2.2 ± 0.7	1.9 ± 0.3	2.5 ± 1.1	2.3 ± 0.6	𝑃=0.179

CCRCC: clear cell renal cell carcinoma, sIL-2R: soluble interleukin-2 receptor, sB7-H3: soluble B7-H3, and sCTLA-4: soluble cytotoxic T lymphocyte associated antigen-4.